Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
StockStory.org on MSN1h
Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, ...
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Hims & Hers offers upbeat forecast, but stock slides after hours
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Hims & Hers posts Q4 beat, issues bullish outlook: why is the stock crashing?
Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.
Hims & Hers Health (NYSE:HIMS) Craters With Weight Loss Drug Issues
It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...
Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
These Stocks Are Moving the Most Today: Super Micro, Nvidia, Home Depot, Palantir, Hims & Hers, Eli Lilly, MicroStrategy, and More
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...